Neuronal effects of 4-t-Butylcatechol: a model for catechol-containing antioxidants

Toxicol Appl Pharmacol. 2008 Apr 15;228(2):247-55. doi: 10.1016/j.taap.2007.12.001. Epub 2007 Dec 14.

Abstract

Many herbal medicines and dietary supplements sold as aids to improve memory or treat neurodegenerative diseases or have other favorable effects on the CNS contain a catechol or similar 1,2-dihydroxy aromatic moiety in their structure. As an approach to isolate and examine the neuroprotective properties of catechols, a simple catechol 4-t-Butylcatechol (TBC) has been used as a model. In this study, we investigated the effects of TBC on lipopolysaccharide (LPS)-activated microglial-induced neurotoxicity by using the in vitro model of coculture murine microglial-like cell line HAPI with the neuronal-like human neuroblastoma cell line SH-SY5Y. We also examined the effects of TBC on 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in human dopaminergic neuroblastoma SH-SY5Y cells. TBC at concentrations from 0.1-10 microM had no toxic effect on HAPI cells and SH-SY5Y cells, and it inhibited LPS (100 ng/ml)-induced increases of superoxide, intracellular ROS, gp91(Phox), iNOS and a decrease of HO-1 in HAPI cells. Under coculture condition, TBC significantly reduced LPS-activated microglia-induced dopaminergic SH-SY5Y cells death. Moreover, TBC (0.1-10 microM) inhibited 6-OHDA-induced increases of intracellular ROS, iNOS, nNOS, and a decrease of mitochondria membrane potential, and cell death in SH-SY5Y cells. However, the neurotoxic effects of TBC (100 microM) on SH-SY5Y cells were also observed including the decrease in mitochondria membrane potential and the increase in COX-2 expression and cell death. TBC-induced SH-SY5Y cell death was attenuated by pretreatment with NS-398, a selective COX-2 inhibitor. In conclusion, this study suggests that TBC might possess protective effects on inflammation- and oxidative stress-related neurodegenerative disorders. However, the high concentration of TBC might be toxic, at least in part, for increasing COX-2 expression.

Publication types

  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / pharmacology*
  • Catechols / pharmacology*
  • Cell Line
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Coculture Techniques
  • Cyclooxygenase 2 / metabolism
  • Cyclooxygenase Inhibitors / pharmacology
  • Dose-Response Relationship, Drug
  • Heme Oxygenase-1 / metabolism
  • Humans
  • Lipopolysaccharides / pharmacology
  • Membrane Glycoproteins / metabolism
  • Membrane Potential, Mitochondrial / drug effects
  • Microglia / cytology
  • Microglia / drug effects
  • Microglia / metabolism
  • NADPH Oxidase 2
  • NADPH Oxidases / metabolism
  • Neurons / cytology
  • Neurons / drug effects*
  • Neurons / metabolism
  • Nitric Oxide Synthase Type I / antagonists & inhibitors
  • Nitric Oxide Synthase Type I / metabolism
  • Nitric Oxide Synthase Type II / antagonists & inhibitors
  • Nitric Oxide Synthase Type II / metabolism
  • Nitrobenzenes / pharmacology
  • Oxidative Stress / drug effects
  • Oxidopamine / pharmacology*
  • Reactive Oxygen Species / metabolism
  • Sulfonamides / pharmacology

Substances

  • Antioxidants
  • Catechols
  • Cyclooxygenase Inhibitors
  • Lipopolysaccharides
  • Membrane Glycoproteins
  • Nitrobenzenes
  • Reactive Oxygen Species
  • Sulfonamides
  • N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
  • tert-butylcatechol
  • Oxidopamine
  • Nitric Oxide Synthase Type I
  • Nitric Oxide Synthase Type II
  • HMOX1 protein, human
  • Heme Oxygenase-1
  • Cyclooxygenase 2
  • Cybb protein, rat
  • NADPH Oxidase 2
  • NADPH Oxidases